Valuation: Capricor Therapeutics, Inc.

Market Cap 1.34B 1.18B 1.08B 1.01B 1.91B 128B 1.94B 12.98B 5.05B 62.94B 5.05B 4.94B 218B P/E 2026 *
-39.2x
P/E 2027 * -35.5x
Enterprise Value 1.34B 1.18B 1.08B 1.01B 1.91B 128B 1.94B 12.98B 5.05B 62.94B 5.05B 4.94B 218B EV / Sales 2026 *
11.4x
EV / Sales 2027 * 11x
Free-Float
90.53%
Yield 2026 *
-
Yield 2027 * -
1 day-5.79%
1 week-7.82%
Current month-8.89%
1 month-16.13%
3 months-30.74%
6 months-16.04%
Current year-23.98%
1 week 21.64
Extreme 21.645
24.99
1 month 21.64
Extreme 21.645
30.93
Current year 21.06
Extreme 21.0601
36.82
1 year 4.3
Extreme 4.3
40.37
3 years 2.68
Extreme 2.68
40.37
5 years 2.56
Extreme 2.56
40.37
10 years 0.88
Extreme 0.88
44.39
Manager TitleAgeSince
Chief Executive Officer 62 20/11/2013
Director of Finance/CFO 40 01/01/2018
Chief Tech/Sci/R&D Officer - 13/05/2025
Director TitleAgeSince
Chairman 70 01/11/2013
Director/Board Member 68 20/11/2013
Director/Board Member 79 20/11/2013
Date Insider Type Main position Quantity % Market Cap.
06-25Fiscal year

General Counsel

72,300 0.1248%
06-25Fiscal year

Chief Financial Officer

72,300 0.1248%
06-24Fiscal year

Chief Financial Officer

1,200 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-5.90%-7.82%+121.62%+399.77% 1.34B
-2.14%+3.51%+74.50%+131.10% 59.1B
-0.93%+4.05%+73.64%+90.53% 55.19B
-2.60%+0.88%-13.60%-10.09% 24.67B
+0.67%+7.32%+15.94%+455.64% 24.19B
+0.64%+14.41%+44.27%-3.20% 19.69B
-2.19%+6.34%+39.72%-29.60% 17.56B
+3.58%+25.11%+196.41%+363.46% 16.22B
+4.91%+25.24%+44.61% - 14.84B
-0.32%+2.46%+25.94%+187.71% 14.04B
Average -0.42%+5.18%+62.30%+176.15% 24.68B
Weighted average by Cap. -0.54%+6.26%+58.59%+137.94%

Financials

2026 *2027 *
Net sales 118M 103M 95.25M 88.41M 168M 11.26B 170M 1.14B 444M 5.53B 443M 434M 19.17B 122M 107M 98.68M 91.6M 174M 11.67B 176M 1.18B 460M 5.73B 459M 449M 19.86B
Net income -28.4M -24.88M -22.91M -21.27M -40.39M -2.71B -40.93M -274M -107M -1.33B -107M -104M -4.61B -48.17M -42.19M -38.86M -36.07M -68.49M -4.59B -69.41M -465M -181M -2.26B -181M -177M -7.82B
Net Debt - -
Logo Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Employees
231
Date Price Change Volume
06/07/26 $21.95 -5.45% 1,288,542
02/07/26 $23.21 +0.61% 1,641,256
01/07/26 $23.07 -4.19% 1,807,652
30/06/26 $24.08 +1.18% 1,858,849
29/06/26 $23.80 -9.98% 3,243,527
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
23.21USD
Average target price
53.60USD
Spread / Average Target
+130.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPR Stock